Extract
Obstructive sleep apnoea (OSA) is increasingly recognised as a risk factor for stroke [1]. However, the incidence of stroke in patients investigated for OSA has been assessed in a limited number of studies reporting conflicting results on the association between the apnoea-hypopnea index (AHI) and stroke incidence [1–3]. As OSA is a very heterogeneous condition, the identification of subgroups of patients at high risk for stroke would be clinically desirable, in order to implement preventive actions [1]. Population-based studies have demonstrated that the sleep apnoea specific hypoxic burden (SASHB), an easily derived signal from polysomnography (PSG), predicts cardiovascular mortality and incident heart failure [4, 5]. A recent study has demonstrated that night-time heart rate variability (HRV) might play an important role in the association between OSA and the cerebral small vessel disease, which is responsible for a substantial proportion of strokes [6]. Whether physiological markers of SASHB and HRV might be useful in clinical setting for identifying those patients with OSA at risk for stroke remains to be determined. Within a large multicentre clinic-based cohort of patients investigated for OSA, we hypothesised that PSG-derived indices of SASHB and HRV could predict stroke incidence.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Blanchard has nothing to disclose.
Conflict of interest: Dr. Gerves-Pinquie has nothing to disclose.
Conflict of interest: Dr. Feuilloy has nothing to disclose.
Conflict of interest: Dr. Le Vaillant has nothing to disclose.
Conflict of interest: Dr. Trzepizur has nothing to disclose.
Conflict of interest: Dr. Meslier has nothing to disclose.
Conflict of interest: Dr. Goupil has nothing to disclose.
Conflict of interest: Dr. Pigeanne has nothing to disclose.
Conflict of interest: Dr. Balusson has nothing to disclose.
Conflict of interest: Dr. Oger has nothing to disclose.
Conflict of interest: Dr. Sabil has nothing to disclose.
Conflict of interest: Dr. Girault has nothing to disclose.
Conflict of interest: Dr. GAGNADOUX reports grants and personal fees from RESMED, personal fees and non-financial support from SEFAM, personal fees from CIDELEC, personal fees and non-financial support from NOVARTIS, personal fees from ACTELION, non-financial support from BOEHRINGER INGELHEIM, personal fees and non-financial support from AIR LIQUIDE SANTE, non-financial support from ASTEN, outside the submitted work.
- Received September 23, 2020.
- Accepted November 2, 2020.
- Copyright ©ERS 2020
LIBRARY USERS
Log in through your institution
Purchase access
